PCM
ASBP

Prelude Capital Management’s Aspire Biopharma ASBP Stock Holding History

Prelude Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-39
Closed -$478K – 1662
2022
Q3 		$478K Buy
+39
New +$471K 0.02% 675

Other funds holding ASBP

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Prelude Capital Management's ASBP Position: Q4 2022 in Review

Prelude Capital Management sold out of Aspire Biopharma (ASBP) in Q4 2022, closing a stake of 39 shares — an estimated $478K sold.

Prelude Capital Management first reported a position in ASBP in Q3 2022 and held it in 1 quarter. The position peaked at $478K in Q3 2022. 55 funds tracked by Wall St. Rank hold ASBP as of Q4 2022.

  • Prelude Capital Management reported no remaining Aspire Biopharma position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 39 Aspire Biopharma shares in Q4 2022, an estimated $478K.
  • Prelude Capital Management first reported a position in Aspire Biopharma in Q3 2022 and held it in 1 quarter.
  • Prelude Capital Management's Aspire Biopharma position peaked at $478K in Q3 2022.
  • 55 funds tracked by Wall St. Rank held Aspire Biopharma as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.